Used in research settings as a potent and selective inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), CP-335963 helps modulate cortisol levels within tissues. This activity makes it a valuable tool for studying metabolic disorders such as type 2 diabetes, obesity, and metabolic syndrome. By blocking 11β-HSD1 in liver and adipose tissues, it reduces local cortisol exposure, which can improve insulin sensitivity and glucose metabolism in preclinical models. It has also been employed to investigate the role of intracellular glucocorticoid regulation in cognitive function and inflammation. Due to its pharmacological profile, it supports the development of therapeutics targeting glucocorticoid-related pathologies, although it remains primarily a research compound and is not used clinically.